Novo Nordisk Braced For China Insulin Scheme Impact
Access Comes At A Price
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.
